Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003095 · ClinicalTrials.gov registry record
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 26
- Enrollment target
NCT00003095: Completed study, sponsored by SWOG Cancer Research Network.
NCT00003095 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003095 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers. PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine axillary lymph nodes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1997-11 |
| Est. Completion | 2001-02 |
What the finished NCT00003095 record still lists
NCT00003095 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00003095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003095 about?
NCT00003095 is a clinical study titled "S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers. PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine ax...
What is the current status of trial NCT00003095?
This trial is currently completed. The enrollment target is 26 participants. The study started on 1997-11. Estimated completion is 2001-02.
Who is sponsoring clinical trial NCT00003095?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia